Efficacy and steroid-sparing effect of benralizumab: has it an advantage over its competitors? (Q64113098)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31024635 AND SRC:MED&resulttype=core&format=json

23 April 2020

title

Efficacy and steroid-sparing effect of benralizumab: has it an advantage over its competitors? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31024635 AND SRC:MED&resulttype=core&format=json

Randomized Clinical Trials

23 April 2020

main subject

Eosinophils

0 references

0 references

author

Francesco Menzella

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31024635 AND SRC:MED&resulttype=core&format=json

23 April 2020

Carla Galeone

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31024635 AND SRC:MED&resulttype=core&format=json

23 April 2020

author name string

Mirella Biava

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31024635 AND SRC:MED&resulttype=core&format=json

23 April 2020

Diego Bagnasco

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31024635 AND SRC:MED&resulttype=core&format=json

23 April 2020

Anna Simonazzi

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31024635 AND SRC:MED&resulttype=core&format=json

23 April 2020

Patrizia Ruggiero

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31024635 AND SRC:MED&resulttype=core&format=json

23 April 2020

Nicola Facciolongo

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31024635 AND SRC:MED&resulttype=core&format=json

23 April 2020

language of work or name

English

0 references

publication date

15 April 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31024635 AND SRC:MED&resulttype=core&format=json

23 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31024635 AND SRC:MED&resulttype=core&format=json

23 April 2020

volume

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31024635 AND SRC:MED&resulttype=core&format=json

23 April 2020

page(s)

212580

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31024635 AND SRC:MED&resulttype=core&format=json

Eosinophilic Inflammation in Asthma

23 April 2020

cites work

1 reference

12 December 2020

Disorders of neutrophil function

1 reference

12 December 2020

Effect of Sch 55700, a humanized monoclonal antibody to human interleukin-5, on eosinophilic responses and bronchial hyperreactivity

1 reference

12 December 2020

Structure of the activation domain of the GM-CSF/IL-3/IL-5 receptor common beta-chain bound to an antagonist

1 reference

12 December 2020

Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response.

1 reference

12 December 2020

Interleukin-5 induces CD34( ) eosinophil progenitor mobilization and eosinophil CCR3 expression in asthma

1 reference

12 December 2020

The impact of corticosteroids on growth and bone health

1 reference

12 December 2020

Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway

1 reference

12 December 2020

The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity

1 reference

12 December 2020

Anti–IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics

1 reference

12 December 2020

Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics

1 reference

12 December 2020

Sputum CD34 IL-5Ralpha cells increase after allergen: evidence for in situ eosinophilopoiesis

1 reference

12 December 2020

IL-5 and granulocyte-macrophage colony-stimulating factor activate STAT3 and STAT5 and promote Pim-1 and cyclin D3 protein expression in human eosinophils

1 reference

12 December 2020

Nonfucosylated therapeutic IgG1 antibody can evade the inhibitory effect of serum immunoglobulin G on antibody-dependent cellular cytotoxicity through its high binding to FcgammaRIIIa

1 reference

12 December 2020

Eosinophilopoiesis at the cross-roads of research on development, immunity and drug discovery

1 reference

12 December 2020

Anti-IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levels

1 reference

12 December 2020

Mepolizumab and exacerbations of refractory eosinophilic asthma

1 reference

12 December 2020

Mepolizumab for prednisone-dependent asthma with sputum eosinophilia

1 reference

12 December 2020

Glucocorticoid resistance in inflammatory diseases.

1 reference

12 December 2020

IL-5- and eosinophil-mediated inflammation: from discovery to therapy

1 reference

12 December 2020

Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma

1 reference

12 December 2020

Pharmacokinetics and Pharmacodynamics of Mepolizumab, an Anti-Interleukin-5 Monoclonal Antibody

1 reference

12 December 2020

Reslizumab for Poorly Controlled, Eosinophilic Asthma

1 reference

12 December 2020

Optimal management of severe/refractory asthma

1 reference

12 December 2020

Molecular and clinical rationale for therapeutic targeting of interleukin‐5 and its receptor

1 reference

12 December 2020

Pulmonary innate lymphoid cells are major producers of IL-5 and IL-13 in murine models of allergic asthma

1 reference

12 December 2020

Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial

1 reference

12 December 2020

Targeting eosinophils in allergy, inflammation and beyond

1 reference

12 December 2020

The consequences of not having eosinophils.

1 reference

12 December 2020

Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia

1 reference

12 December 2020

Glucocorticoid sensitivity in health and disease

1 reference

12 December 2020

International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma

1 reference

12 December 2020

Eosinophils in the lung - modulating apoptosis and efferocytosis in airway inflammation.

1 reference

12 December 2020

Mepolizumab treatment in patients with severe eosinophilic asthma

1 reference

12 December 2020

Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma

1 reference

12 December 2020

Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study

1 reference

12 December 2020

A randomized trial of benralizumab, an antiinterleukin 5 receptor α monoclonal antibody, after acute asthma

1 reference

12 December 2020

An emphasis on molecular mechanisms of anti-inflammatory effects and glucocorticoid resistance

1 reference

12 December 2020

Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials

1 reference

12 December 2020

Biologic therapies targeting eosinophils: current status and future prospects

1 reference

12 December 2020

Multifaceted roles of cysteinyl leukotrienes in eliciting eosinophil granule protein secretion

1 reference

12 December 2020

Eosinophilic airway inflammation: role in asthma and chronic obstructive pulmonary disease

1 reference

12 December 2020

Reductions in eosinophil biomarkers by benralizumab in patients with asthma.

1 reference

12 December 2020

The Role and Immunobiology of Eosinophils in the Respiratory System: a Comprehensive Review

1 reference

12 December 2020

Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies

1 reference

12 December 2020

Long-term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-center, Open-label, Phase IIIb Study

1 reference

12 December 2020

Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial

1 reference

12 December 2020

Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial

1 reference

12 December 2020

The clinical profile of benralizumab in the management of severe eosinophilic asthma

1 reference

12 December 2020

Efficacy and Safety of Anti-Interleukin-5 Therapy in Patients with Asthma: A Systematic Review and Meta-Analysis

1 reference

12 December 2020

Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial.

1 reference

12 December 2020

Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma

1 reference

12 December 2020

Mepolizumab Attenuates Airway Eosinophil Numbers, but Not Their Functional Phenotype, in Asthma.

1 reference

12 December 2020

Weight-adjusted Intravenous Reslizumab in Severe Asthma with Inadequate Response to Fixed-Dose Subcutaneous Mepolizumab

1 reference

12 December 2020

Long-term Safety and Efficacy of Reslizumab in Patients with Eosinophilic Asthma

1 reference

12 December 2020

Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab

1 reference

12 December 2020

1 reference

12 December 2020

Benralizumab: From the Basic Mechanism of Action to the Potential Use in the Biological Therapy of Severe Eosinophilic Asthma.

1 reference

12 December 2020

Autoimmune Responses in Severe Asthma

1 reference

12 December 2020

Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma

1 reference

12 December 2020

The Severe Asthma Network in Italy (SANI): findings and perspectives

1 reference

12 December 2020

Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial

1 reference

12 December 2020

Anti-IL-5 and IL-5Ra: Efficacy and Safety of New Therapeutic Strategies in Severe Uncontrolled Asthma

1 reference

12 December 2020

Severe refractory asthma: current treatment options and ongoing research

1 reference

12 December 2020

Modulation of blood inflammatory markers by benralizumab in patients with eosinophilic airway diseases

1 reference

12 December 2020

Identifiers

DOI

10.7573/DIC.212580

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31024635 AND SRC:MED&resulttype=core&format=json

23 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31024635 AND SRC:MED&resulttype=core&format=json

23 April 2020

PubMed publication ID

31024635

1 reference